Eikon Therapeutics, the high‑profile startup built around protein dynamics technology and led by former Merck executives, filed to go public as it looks to bankroll a clutch of clinical cancer and neuro programs. The S‑1 outlines programs in four candidates with several in mid‑stage trials; an interim analysis of a Phase 2/3 melanoma study is expected later this year. Eikon’s IPO filing follows a private‑market rebound and reflects renewed investor interest in platform biotechs that combine novel discovery engines with partner deal flow. The company intends to use proceeds for clinical development, platform expansion and potential strategic transactions.